Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 4.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,611 shares of the biopharmaceutical company’s stock after acquiring an additional 215 shares during the period. Nisa Investment Advisors LLC’s holdings in Halozyme Therapeutics were worth $358,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Heck Capital Advisors LLC purchased a new stake in Halozyme Therapeutics in the fourth quarter valued at $29,000. Bessemer Group Inc. boosted its position in shares of Halozyme Therapeutics by 62.9% during the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 207 shares in the last quarter. Park Place Capital Corp boosted its position in shares of Halozyme Therapeutics by 20.1% during the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 182 shares in the last quarter. UMB Bank n.a. boosted its position in shares of Halozyme Therapeutics by 267.4% during the 1st quarter. UMB Bank n.a. now owns 1,319 shares of the biopharmaceutical company’s stock worth $84,000 after acquiring an additional 960 shares in the last quarter. Finally, Parallel Advisors LLC boosted its position in shares of Halozyme Therapeutics by 12.5% in the 1st quarter. Parallel Advisors LLC now owns 1,875 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 208 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on HALO shares. The Goldman Sachs Group started coverage on Halozyme Therapeutics in a research note on Thursday, July 10th. They set a “neutral” rating and a $55.00 price objective for the company. JPMorgan Chase & Co. increased their target price on Halozyme Therapeutics from $58.00 to $60.00 and gave the stock a “neutral” rating in a research note on Wednesday. Wells Fargo & Company raised their price objective on Halozyme Therapeutics from $60.00 to $65.00 and gave the company an “equal weight” rating in a research note on Wednesday, May 7th. Benchmark downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 7th. Finally, HC Wainwright reissued a “buy” rating and set a $72.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, May 29th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Halozyme Therapeutics has a consensus rating of “Hold” and a consensus price target of $62.70.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $56.43, for a total value of $1,128,600.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $41,403,763.17. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jeffrey William Henderson sold 4,497 shares of Halozyme Therapeutics stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $60.37, for a total value of $271,483.89. Following the sale, the director directly owned 28,611 shares in the company, valued at approximately $1,727,246.07. The trade was a 13.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,497 shares of company stock worth $3,533,884 over the last ninety days. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Trading Up 2.5%

Shares of HALO opened at $58.01 on Thursday. The company has a current ratio of 8.39, a quick ratio of 7.30 and a debt-to-equity ratio of 3.13. The firm has a market capitalization of $7.15 billion, a P/E ratio of 15.43, a price-to-earnings-growth ratio of 0.38 and a beta of 1.15. The stock’s fifty day simple moving average is $54.68 and its 200 day simple moving average is $57.08. Halozyme Therapeutics, Inc. has a twelve month low of $42.01 and a twelve month high of $70.51.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, May 6th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.13. The business had revenue of $264.86 million for the quarter, compared to analyst estimates of $231.21 million. Halozyme Therapeutics had a return on equity of 136.91% and a net margin of 44.76%. The business’s quarterly revenue was up 35.2% on a year-over-year basis. During the same period last year, the company posted $0.79 EPS. On average, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.